New diabetes drug safety check underway in pakistan

NCT ID NCT05164263

Recruiting now Disease control Sponsor: Getz Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is checking how safe and well-tolerated the diabetes drug empagliflozin (taken with or without metformin) is in Pakistani adults with type 2 diabetes. About 2000 people aged 18-65 with poorly controlled blood sugar will be followed for 6 months. The study will track side effects like low blood sugar, infections, and dehydration, and also measure how well the drug controls blood sugar and weight.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFICACY, SELF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EFFICACY, SELF SAFETY ISSUES TYPE II DIABETES MELLITUS

Contacts and locations

Locations

Agha Khan univeristy hospital
RECRUITING

Nairobi, Kenya, Kenya
Kabul University of Medical Sciences(KUMS)
COMPLETED

Kabul, Afghanistan, Afghanistan
Lagos University Teaching Hospital
RECRUITING

Lagos, Nigeria, Nigeria
NHK
COMPLETED

Kandy, Kandy, Sri Lanka
National hospital Sri Lanka
COMPLETED

Colombo, Colombo, Sri Lanka
Umar Diabetes Foundation
COMPLETED

Islamabad, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.